Hormone therapy and the risk of stroke after acute myocardial infarction in postmenopausal women

Journal of the American College of Cardiology

Volumn 38, Issue 5, 2001, Pages 1297-1301

  Angeja, Brad G ^a,g   Shlipak, Michael G ^a,b   Go, Alan S ^a,c   Johnston, S Claiborne ^a   Frederick, Paul D ^d   Canto, John G ^e   Barron, Hal V ^a,f   Grady, Deborah ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c DIVISION OF RESEARCH   (United States)

^d Ovation Research Group   (United States)

^e UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^f GENENTECH INC   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; FIBRINOLYTIC THERAPY; HEART CATHETERIZATION; HORMONAL THERAPY; HUMAN; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; POSTMENOPAUSE; PRIORITY JOURNAL; RISK FACTOR; SCORING SYSTEM; SEX DIFFERENCE; STATISTICAL ANALYSIS; STROKE;

AGE DISTRIBUTION; AGED; BRAIN ISCHEMIA; CEREBRAL HEMORRHAGE; CEREBROVASCULAR ACCIDENT; ESTROGEN REPLACEMENT THERAPY; FEMALE; FIBRINOLYTIC AGENTS; HOSPITAL MORTALITY; HOSPITALIZATION; HUMANS; LOGISTIC MODELS; MIDDLE AGED; MULTIVARIATE ANALYSIS; MYOCARDIAL INFARCTION; PATIENT SELECTION; POSTMENOPAUSE; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; REGISTRIES; RISK FACTORS; TREATMENT OUTCOME; UNITED STATES;

EID: 0035500051     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(01)01551-0     Document Type: Article

References (22)

1. Hormone therapy to prevent disease and prolong life in postmenopausal women
2. A prospective, observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease
3. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women: Heart and Estrogen/progestin Replacement Study (HERS) Research Group
4. Ischemic stroke risk with oral contraceptives: A meta-analysis
5. Oral contraceptives and the risk of subarachnoid hemorrhage: A meta-analysis
6. Factors associated with ischemic stroke during aspirin therapy in atrial fibrillation: Analysis of 2012 participants in the SPAF I-III clinical trials: The Stroke Prevention in Atrial Fibrillation (SPAF) Investigators
7. Decreased risk of stroke among postmenopausal hormone users: Results from a national cohort
8. Estrogen replacement therapy and stroke
9. Subarachnoid hemorrhage and hormonal factors in women: A population-based case-control study
10. Risk factors for cerebral hemorrhage in the era of well-controlled hypertension: Melbourne Risk Factor Study (MERFS) Group
11. Postmenopausal hormone therapy and risk of stroke: The Heart and Estrogen-progestin Replacement Study (HERS)
12. Stroke after thrombolysis: Mortality and functional outcomes in the GUSTO-I trial: Global Use of Strategies to Open Occluded Coronary Arteries
13. Comparison of primary coronary angioplasry and intravenous thrombolytic therapy for acute myocardial infarction: A quantitative review
14. Death or nonfatal stroke in patients with acute myocardial infarction treated with tissue plasminogen activator: Participants in the national registry, of myocardial infarction 2
15. Risk factors for in-hospital nonhemorrhagic stroke in patients with acute myocardial infarction treated with thrombolysis: Results from GUSTO-I
16. Risk for intracranial hemorrhage after tissue plasminogen activator treatment for acute myocardial infarction: Participants in the national registry of myocardial infarction 2
17. A comparison of the national registry of myocardial infarction 2 with the cooperative cardiovascular project
18. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group
19. Effect of estrogen replacement on risk of recurrent stroke and death in the Women's Estrogen for Stroke Trial (WEST)
20. Postmenopausal hormone therapy increases risk for venous thromboembolic disease: The heart and estrogen/progestin replacement study
21. Association between increased estrogen status and increased fibrinolytic potential in the Framingham Offspring Study
22. Incidence and predictors of bleeding after contemporary, thrombolytic therapy for myocardial infarction: The Global Utilization of Streptokinase and Tissue Plasminogen activator for Occluded coronary arteries (GUSTO) I Investigators